HER2-Targeted Immunoconjugate Reduces Off-Target Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, including surgery, radiation therapy, chemotherapy, and targeted therapy, often face limitations such as low specificity, low efficiency, and adverse side effects, necessitating a novel method for effectively treating cancers like HER2-positive gastric cancer.
Innovation Solution
Development of an immunoconjugate comprising an antibody or its fragment, a functional motif, and a linker, specifically targeting HER2-positive cancer cells with cytotoxic payloads like PE38KDEL or MMAE, to deliver therapeutic agents directly to tumor cells while minimizing off-target toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cancer treatments (chemotherapy, radiation therapy) are used, then cancer cells can be killed, but off-target toxicity and adverse side effects occur
Solution Approach 1:
The treatment system is segmented into distinct functional components: an antibody fragment for target recognition, a linker for controlled delivery, and a cytotoxic payload for tumor cell destruction. This segmentation allows the cytotoxic agent to be delivered specifically to tumor cells via the targeting antibody, minimizing exposure to healthy tissues and reducing off-target toxicity while maintaining anti-tumor activity
Solution Approach 2:
The antibody fragment serves as an intermediary that bridges the cytotoxic payload and the HER2-positive tumor cells. The antibody specifically binds to HER2 receptors on tumor cells, directing the cytotoxic agent to the target site and preventing systemic distribution of the toxic agent, thereby reducing adverse side effects while maintaining therapeutic efficacy
2Reliability
If conventional cancer treatments are used, then cancer cells can be killed, but treatment specificity is low
Solution Approach 1:
The immunoconjugate exhibits local quality by concentrating cytotoxic activity specifically at the tumor site through HER2-targeted binding. The antibody fragment provides selective localization to HER2-positive cells, ensuring that the cytotoxic payload is released only at the target site rather than systemically, thereby achieving high treatment specificity while maintaining potent anti-tumor activity
3Reliability
If cytotoxic payloads are delivered systemically, then tumor cells can be killed, but off-target toxicity increases
Solution Approach 1:
The antibody fragment performs preliminary targeting action by specifically binding to HER2 receptors on tumor cells before the cytotoxic payload is activated or released. This preliminary localization ensures that the cytotoxic agent is delivered precisely to the intended target, maintaining cytotoxic efficacy while minimizing exposure to healthy tissues and reducing off-target toxicity
Data Source
AI summary
Disclosed herein is an immunoconjugate comprising an antibody, a functional motif, and a linker connecting the functional motif to the antibody. According to embodiments of the present disclosure, the antibody may recognize tumor-associated antigens (TAAs), and serves as a targeting module for delivering the functional motif connected therewith to the tumor cells thereby inhibiting tumor growth or detecting the distribution of tumor cells. Also disclosed herein are methods of treating cancers and methods of diagnosing cancers by use of the present immunoconjugate.